Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Change in Accured Expenses (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Change in Accured Expenses for 16 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 476.92% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 million, a 554.82% increase, with the full-year FY2025 number at $4.2 million, up 554.82% from a year prior.
  • Change in Accured Expenses was $3.5 million for Q4 2025 at Lemaitre Vascular, up from $2.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.3 million in Q3 2024 to a low of -$5.3 million in Q1 2025.
  • A 5-year average of $339250.0 and a median of $252000.0 in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: crashed 237.23% in 2021, then soared 9157.14% in 2023.
  • Lemaitre Vascular's Change in Accured Expenses stood at -$1.2 million in 2021, then soared by 140.19% to $469000.0 in 2022, then soared by 400.21% to $2.3 million in 2023, then crashed by 139.34% to -$923000.0 in 2024, then surged by 476.92% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Change in Accured Expenses are $3.5 million (Q4 2025), $2.0 million (Q3 2025), and $4.0 million (Q2 2025).